CT Enterography -- CTE -- Superior to Capsule Endoscopy for Detecting Crohn's Disease in Small Bowel; Study Results Point to Expanding Role for CTE and VoLumen.

LAKE SUCCESS, N.Y. -- E-Z-EM, Inc., (NASDAQ:EZEM) today announced that results of a study presented at the 2005 Digestive Disease Week (DDW) meeting show that computed tomography enterography (CTE) is superior to capsule endoscopy in detecting Crohn's Disease in the small bowel as measured by specificity and overall accuracy, and provided comparable sensitivity. CTE is a study that uses an oral contrast, like VoLumen(R) low Hounsfield value oral contrast, to distend the bowel and improve bowel wall visualization.

The 42 patient study -- "Small Bowel (SB) Imaging in Crohn's Disease (CD): A Prospective, Blinded, 4-Way Comparison Trial" by Dr. Craig A. Solem, et al, of the Mayo Clinic evaluated the sensitivity, specificity and accuracy of CT Enterography (CTE), ileocolonoscopy (IC), capsule endoscopy (CE), and small bowel follow-through (SBFT) in the diagnosis of Crohn's disease in the small bowel. The study showed that CTE with VoLumen and CE "have similarly high sensitivity (82% and 83% respectively) for detecting active Crohn's disease, and appear to be superior to IC and SBFT" (74% and 65% respectively). The specificity for CTE with VoLumen was 89%, as compared to 100% for IC, 94% for SBFT, and only 53% for CE. As measured by general accuracy, CTE with VoLumen was comparable to IC (85% and 86% respectively) and superior to both CE (67%) and SBFT (79%).

Commenting on the results, Anthony A. Lombardo, President and CEO of E-Z-EM, said, "Small bowel imaging is often done prior to capsule endoscopy due to the risk of capsule retention in an undetected blockage. These results strongly suggest that for suspected Crohn's disease, small bowel imaging with CTE can obviate the need for follow-up study with capsule endoscopy. In conjunction with other recently completed research which demonstrated the superiority of VoLumen low Hounsfield value oral contrast in CTE and other abdominal imaging procedures, this study points to an expanding role for CTE and VoLumen in the diagnosis of Crohn's disease. In fact, researchers involved in this study have since standardized the use of VoLumen in their CTE procedures. We are delighted with these results and look forward to a growing role of VoLumen in CT imaging."

DDW is a major medical gathering sponsored and hosted by four well-respected societies focused on diseases of the gastrointestinal tract: The American Association for the Study of Liver Diseases (AASLD), American Gastroenterological Association (AGA), The American Society for Gastrointestinal Endoscopy (ASGE), Society for Surgery of the Alimentary Tract (SSAT). These prestigious associations represent a combined membership of over 23,700 physicians, researchers, educators and other medical professionals. The meeting is being held from May 14-19 at the McCormick Convention Center in Chicago, IL.

About E-Z-EM, Inc.

E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company recently introduced VoLumen(R) the next generation low density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and PET/CT studies. The Company also offers Empower(R) -- the only family of CT injectors on the market with patented EDA(TM) technology that can help detect contrast extravasation -- and offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system.

The statements made in this document contain certain forward-looking statements. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates" or variations of such words and similar expressions, are intended to identify such forward-looking statements. The forward-looking statements contained in this release may involve numerous risks and uncertainties, known and unknown, beyond the Company's control. Such risks and uncertainties include the ability of the Company to develop its products, the results of ongoing medical research for, market acceptance and future sales of VoLumen, future actions by the FDA or other regulatory agencies, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended November 27, 2004 and its Annual Report on Form 10-K for the fiscal year ended May 29, 2004. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements, and investors are cautioned not to place undue reliance on the forward-looking statements included in this release.